Open access · CC-BY
via OpenAlex
Testing the Translational Potential of Rapamycin on Healthy Aging
Innovation in Aging · 2025
Abstract
Abstract Treatment with mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition), an inhibitor of the mechanistic Target Of Rapamycin Complex One (mTORC1) protein kinase, has been repeatedly demonstrated to extend lifespan and prevent or delay several age-related diseases in diverse model systems. Concerns over the risk of adverse side effects, including immunosuppression and metabolic disruptions, have cautiously limited the clinical translation of rapamycin and its analogs as a treatment for aging associated conditions. Despite potential risks, an increasing number of physically active adults are taking the mTOR inhibitor rapamycin off label with the goal of extending healthspan(definition). A working model suggests that while inhibition of mTORC1 promotes healthy aging, many of the negative side effects of rapamycin are associated with inhibition of a second mTOR complex, mTORC2. Differences in the kinetics and molecular mechanisms by which rapamycin inhibits mTORC1 and mTORC2 suggest that a therapeutic window for rapamycin could be exploited using intermittent dosing schedules or alternative rapalogs that may enable more selective inhibition of mTORC1. However, the optimal dosing schedules and the long-term efficacy of such interventions in humans is unknown. Further, it remains unknown how different rapamycin dosing schedules impact the health benefits of exercise. Here, I will provide the rationale, experimental design, and updates for two ongoing human clinical trials aimed to determine the safety, pharmacokinetics, pharmacodynamics, and efficacy of rapamycin and rapalogs on several clinically oriented outcomes. I will also share new insights from integrated multi-omics studies that reveal the impact of different rapamycin dosing schedules on the molecular and metabolic adaptations to exercise in older mice. Results from these pre-clinical and early phase studies will help guide the design of future clinical trials to determine whether rapamycin can be used safely to inhibit mTORC1 for the treatment and prevention of age-related diseases in humans.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1093/geroni/igaf122.406
- Canonical
- link ↗
- Fetched
- 2026-10-07 MST
Cite this
APA
Konopka, A.R. (2025). Testing the Translational Potential of Rapamycin on Healthy Aging. <em>Innovation in Aging</em>. https://doi.org/10.1093/geroni/igaf122.406
Vancouver
Konopka AR. Testing the Translational Potential of Rapamycin on Healthy Aging. Innovation in Aging. 2025. doi:10.1093/geroni/igaf122.406.
BibTeX
@article{adam2025Testin,
title = {Testing the Translational Potential of Rapamycin on Healthy Aging},
author = {Adam R. Konopka},
journal = {Innovation in Aging},
year = {2025},
doi = {10.1093/geroni/igaf122.406},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Aging Cell 2015
Open access · CC-BY
Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system
Preprints.org 2021
Preprint · CC-BY
Rapamycin and Rapalogs
The Journals of Gerontology Series A 2016
Open access · OA
Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island
Nature Communications 2019
Open access · CC-BY
A novel rapamycin analog is highly selective for mTORC1 in vivo
Expert Reviews in Molecular Medicine 2023
Open access · CC-BY
Autophagic mechanisms in longevity intervention: role of natural active compounds
Cold Spring Harbor Perspectives in Medicine 2016
Preprint · OA